GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » Retained Earnings

Atossa Therapeutics (Atossa Therapeutics) Retained Earnings : $-186.29 Mil (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Atossa Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Atossa Therapeutics's retained earnings for the quarter that ended in Dec. 2023 was $-186.29 Mil.

Atossa Therapeutics's quarterly retained earnings declined from Jun. 2023 ($-172.31 Mil) to Sep. 2023 ($-178.53 Mil) and declined from Sep. 2023 ($-178.53 Mil) to Dec. 2023 ($-186.29 Mil).

Atossa Therapeutics's annual retained earnings declined from Dec. 2021 ($-129.23 Mil) to Dec. 2022 ($-156.19 Mil) and declined from Dec. 2022 ($-156.19 Mil) to Dec. 2023 ($-186.29 Mil).


Atossa Therapeutics Retained Earnings Historical Data

The historical data trend for Atossa Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Retained Earnings Chart

Atossa Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -94.07 -111.90 -129.23 -156.19 -186.29

Atossa Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -156.19 -162.48 -172.31 -178.53 -186.29

Atossa Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Atossa Therapeutics  (NAS:ATOS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Atossa Therapeutics (Atossa Therapeutics) Business Description

Traded in Other Exchanges
Address
107 Spring Street, Seattle, WA, USA, 98104
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Executives
Gregory L Weaver director 185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Heather Rees officer: SVP, Finance and Accounting C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE WA 98104
Kyle Guse officer: CFO & General Counsel C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98102
H. Lawrence Remmel director C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
Shu-chih Chen director, 10 percent owner, officer: Chief Scientific Officer C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112
Steven C Quay director, 10 percent owner, officer: CEO 22026 20TH AVENUE S E, SUITE 102, BOTHELL WA 98021
Scott Youmans officer: Chief Operating Officer ATOSSA GENETICS INC., 2345 EASTLAKE AVE. E, SUITE 201, SEATTLE WA 98102
John E Sawyer officer: See Remarks C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98021
Christopher S. Destro officer: SVP, Sales and Marketing C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Peter J. Carbonaro officer: Sr. Vice President, Operations C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Ben R Chen officer: Sr. VP of Glob. Reg. Affairs 1616 EASTLAKE AVENUE EAST, SUITE 510, SEATTLE WA 98102
Richard I Steinhart director 125 ELM STREET, NEW CANAAN CT 06840
Alexander D Cross director C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO CA 92121
Stephen J Galli director C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
John Barnhart director C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112